Fellow Eye RRD Risk Stratified by Hyaloid Status on OCT

Fellow Eye RRD Risk Stratified by Hyaloid Status on OCT

In patients with a rhegmatogenous retinal detachment (RRD) in one eye, it is important to evaluate and monitor the fellow eye as there is an elevated risk for developing an RRD. Traditional risk factors that may alter risk of RRD development in the fellow eye may include posterior vitreous detachment (PVD) status, presence or absence of lattice degeneration, family history of retinal detachment, and/or history of high myopia. The rate of bilateral sequential RRD ranges from 10% to 40%, but there is little data available on how to stratify the risk of fellow eye RRD development. The close association of PVD development and RRD risk offers an opportunity to stratify RRD risk in the fellow eye by evaluating the hyaloid status on OCT at presentation.

In this retrospective, single center, consecutive cohort study over 10 years, the authors evaluated clinical records of all patients presenting with RRD and reviewed OCT imaging to classify the hyaloid status at initial presentation. The patients were then observed for a mean of 5.7 years for RRD development in the fellow eye.

In total, 1,049 patients with an RRD were identified, and the overall incidence of bilateral sequential RRD was 14.6%. Of the 1,049 patients with an RRD, OCT imaging was available for 582 eyes (55%) at initial presentation. By OCT review at baseline, the hyaloid was attached in 353 (51.7%) fellow eyes whereas a PVD was noted in 229 (39%) of fellow eyes. During the follow-up, a subsequent RRD occurred in 28 (8%) fellow eyes with an attached hyaloid compared to 7 (3%) fellow eyes with a PVD on presentation (P = .02). Furthermore, of the 353 eyes with an attached hyaloid at baseline, 116 (33%) developed a PVD during the study follow-up with a 23.7% frequency of sequential RRD development.

Overall, retinal tears were noted in 119 (11%) fellow eyes (excluding fellow eyes with RRD) during follow-up. Furthermore, at PVD development in fellow eyes with an attached hyaloid at presentation, 21 (18%) eyes developed a retinal tear.

In terms of relative risk, the study found that an attached hyaloid on OCT of the fellow eye at initial RRD presentation to be a significant risk factor for RRD development in the fellow eye. They noted that lattice degeneration in the fellow eye conferred a 50% increased risk of fellow eye RRD, whereas an attached hyaloid on baseline OCT conferred a 160% increased risk of fellow eye RRD.

These results revealed an increased risk of fellow eye RRD in those with an attached hyaloid on OCT at presentation in comparison to those with a PVD at baseline. The use of OCT to assess the PVD status in fellow eyes of patients presenting with an RRD is a unique tool for patient education and subsequent clinical monitoring. Limitations of this study are inherent in the retrospective nature of the study. Most notably, not all 1,049 eyes with initial RRD had baseline OCT imaging, which limited the size of the cohort for subsequent analysis. Furthermore, the follow-up period was variable for each eye and a longer follow-up until PVD development in all eyes would have been optimal to determine the true rate of sequential RRD.

In summary, this study emphasizes the use of OCT imaging at baseline RRD presentation to evaluate the fellow eye and assist in risk stratification for possible subsequent RRD development.

Details
  • Overview

    April 2023: VBS Literature Update

    Wallsh JO, Langevin ST, Kumar A, Huz J, Falk NS, Bhatnagar P. Fellow eye retinal detachment risk as stratified by hyaloid status on OCT. Ophthalmology. 2023:S0161-6420(23)00105-7. Epub ahead of print.

    Abstract by Samir N. Patel, MD

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Understand how OCT imaging may help to stratify fellow eye rhegmatogenous retinal detachment risk in patients presenting with an initial rhegmatogenous retinal detachment diagnosis
    • Accreditation

       Provided by Evolve Medical Education

      Accreditation Statement
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and Vit Buckle Society.  Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve Medical Education LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

    • Faculty and Disclosures

      Samir N. Patel, MD

      Samir N. Patel, MD

      Retina Vitreous Consultants
      Pittsburgh, PA


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Samir N. Patel, MD, has no financial relationships with ineligible companies

      The Evolve staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Vit Buckle Society.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    0.25 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free